A
Andy Lynn
Publications - 4
Citations - 904
Andy Lynn is an academic researcher. The author has contributed to research in topics: Pharmacokinetics & Alpha-galactosidase. The author has an hindex of 4, co-authored 4 publications receiving 390 citations.
Papers
More filters
Journal ArticleDOI
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Kimberly J. Hassett,Kerry Benenato,Eric Jacquinet,Aisha Lee,Angela Woods,Olga Yuzhakov,Sunny Himansu,Jessica Deterling,Benjamin M. Geilich,Tatiana Ketova,Cosmin Mihai,Andy Lynn,Iain Mcfadyen,Melissa J. Moore,Joseph J. Senn,Matthew G. Stanton,Orn Almarsson,Giuseppe Ciaramella,Luis Brito +18 more
TL;DR: Screening a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model shows that mRNA vaccine tolerability can be improved without affecting potency.
Journal ArticleDOI
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Staci Sabnis,E. Sathyajith Kumarasinghe,Timothy Salerno,Cosmin Mihai,Tatiana Ketova,Joseph J. Senn,Andy Lynn,Alex Bulychev,Iain Mcfadyen,Joyce Chan,Orn Almarsson,Matthew G. Stanton,Kerry Benenato +12 more
TL;DR: Clear structure-activity relationships were developed that resulted in a new amino lipid that affords efficient mRNA delivery in rodent and primate models with optimal pharmacokinetics and is the first example of the ability to safely repeat dose mRNA-containing lipid nanoparticles in non-human primate at therapeutically relevant levels.
Journal ArticleDOI
Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey:
Maja Sedic,Joseph J. Senn,Andy Lynn,Michael E Laska,Michael J. Smith,Stefan Platz,Joseph Beene Bolen,Stephen Hoge,Alex Bulychev,Eric Jacquinet,Victoria Bartlett,Peter F Smith +11 more
TL;DR: Overall, these combined studies indicate that LNP-formulated modified mRNA can be administered by intravenous infusion in 2 toxicologically relevant test species and generate supratherapeutic levels of protein (hEPO) in vivo.
Journal ArticleDOI
Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates
Xuling Zhu,Ling Yin,Matt Theisen,Jenny Zhuo,Summar Siddiqui,Becca Levy,Vladimir Presnyak,Andrea Frassetto,Jaclyn Milton,Timothy Salerno,Kerry Benenato,Joe Milano,Andy Lynn,Staci Sabnis,Kristin E. Burke,Gilles Besin,Christine Lukacs,Lin T. Guey,Patrick Finn,Paolo Martini +19 more
TL;DR: These studies across species demonstrate preclinical proof-of-concept of systemic mRNA therapy for the treatment of Fabry disease and this approach may be useful for other lysosomal storage disorders.